8-K: Candel Therapeutics Elevates Interim CFO Charles Schoch to Permanent Role, Citing Proven Financial Leadership and Successful Capital Raise

Candel Therapeutics, a clinical-stage biopharmaceutical company, has officially appointed Charles Schoch as its Chief Financial Officer, recognizing his instrumental role in the company's financial management and recent successful capital raise.

Summary

• Candel Therapeutics, Inc. announced the unanimous appointment of Charles Schoch as its Chief Financial Officer, effective June 20, 2025.
• Mr. Schoch, age 40, had been serving as the company's interim Chief Financial Officer since January 2024 and will continue as principal financial and accounting officer.
• He joined Candel in November 2021 and has held various financial reporting and accounting positions of increasing responsibility, including VP of Finance and Corporate Controller.
• In connection with his appointment, Mr. Schoch's annual base salary has been increased to $440,000, and he is eligible for an annual bonus with a target amount of 40% of his base salary.
• He was granted an option to purchase 50,000 shares of the company's common stock, with 25% vesting on the one-year anniversary of the effective date and the balance vesting over the next 36 months.
• As interim CFO, Mr. Schoch developed significant investment banking relationships and led a previously announced capital raise with net proceeds of approximately $86 million, following positive Phase 3 clinical trial results for CAN-2409 in localized prostate cancer in December 2024.
• Prior to Candel, Mr. Schoch served as Corporate Controller at Corbus Pharmaceuticals Holdings Inc. from 2019 to 2021 and worked in the health industry assurance practice of PricewaterhouseCoopers LLP from 2013 to 2020.

Sentiment

Score: 8

Explanation: The announcement is highly positive, reflecting a strong internal promotion of a proven financial leader who has already delivered significant value (successful capital raise) and is poised to guide the company through critical future milestones. It signals stability and confidence in the company's financial management.

Positives

• The appointment of Charles Schoch to permanent CFO from an interim role signifies strong internal talent recognition and continuity in financial leadership.
• Mr. Schoch demonstrated exceptional financial and organizational leadership, effectively supporting strategic priorities and maintaining disciplined capital management.
• He successfully led a capital raise that generated approximately $86 million in net proceeds, a significant achievement for a clinical-stage company.
• The company highlights its 'strong financial foundation and disciplined approach to capital allocation and value creation,' positioning it well for sustainable growth.
• Mr. Schoch has built a high-performing finance function overseeing critical operations like SEC reporting, financial planning, and treasury.

Risks

• The timing and advancement of current and future development programs may differ from expectations.
• Expectations regarding the therapeutic benefit of the Company's platforms, including improving overall survival and/or disease-free survival, may not be realized.
• Final data from preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials.
• The Company's ability to efficiently discover and develop product candidates is subject to uncertainties.
• The Company's ability to obtain and maintain regulatory approval of product candidates is not guaranteed.
• The Company's ability to maintain its intellectual property is a continuous challenge.
• The implementation of the Company's business model, including strategic plans for its business and product candidates, carries inherent risks.
• Other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, could impact results.

Future Outlook

Candel Therapeutics plans to advance its clinical pipeline, including preparing for a Biologics License Application (BLA) submission for CAN-2409 in localized prostate cancer. The company aims to execute on its nearand long-term corporate goals, with a continued focus on maintaining financial stability and strategically investing in its future to drive value for stakeholders and deliver clinically meaningful solutions to cancer patients.

Management Comments

• "Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO. He has effectively supported our strategic priorities in a complex market environment while maintaining disciplined capital management. His deep understanding of our business will continue to be instrumental as we advance our clinical pipeline, prepare for our Biologics License Application submission for CAN-2409 in localized prostate cancer, and execute on our nearand long-term corporate goals." Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel.
• "I am honored to continue serving in this role and excited about the opportunities that lie ahead for Candel. Our strong financial foundation and disciplined approach to capital allocation and value creation position us well for sustainable growth. As we advance our promising clinical pipeline and prepare for key milestones, my focus remains on maintaining financial stability while strategically investing in our future. I look forward to working with our talented team on our goals of driving value for our stakeholders and ultimately helping to deliver clinically meaningful solutions to cancer patients in need." Charles Schoch, Chief Financial Officer.

Industry Context

This appointment is a strategic move for Candel Therapeutics, a clinical-stage biopharmaceutical company, as it solidifies its financial leadership during a critical period of clinical pipeline advancement and preparation for potential regulatory submissions. In the capital-intensive biotech industry, a strong and stable financial executive is crucial for managing R&D expenditures, securing funding, and navigating complex market environments. The promotion of an internal candidate who has already demonstrated success, particularly in leading a significant capital raise, signals stability and confidence to investors and aligns with the industry's need for experienced financial stewardship as companies transition from development to potential commercialization.

Comparison to Industry Standards

• The promotion of an interim CFO to a permanent role, especially one who has successfully navigated a significant capital raise (approximately $86 million) and managed financial operations for a clinical-stage biopharmaceutical company, aligns with best practices for leadership continuity and rewarding proven performance in the biotech sector.
• Mr. Schoch's background, including experience as Corporate Controller at Corbus Pharmaceuticals and seven years in PwC's Health Industry assurance practice, provides a strong foundation in biotech financial reporting, internal controls, and capital markets, comparable to the profiles of CFOs at similar clinical-stage companies.
• The compensation package, including a base salary of $440,000 and a 40% target bonus, along with a 50,000-share equity award, is competitive for a CFO at a Nasdaq-listed clinical-stage biopharmaceutical company, reflecting industry standards for attracting and retaining executive talent in a high-growth, high-risk sector.
• The company's focus on advancing a Biologics License Application (BLA) submission for CAN-2409, a pivotal milestone, underscores the need for a financially astute leader to manage the associated costs and potential commercialization strategies, a common challenge for biotech firms transitioning from clinical development to market.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to stable and proven financial leadership, successful capital raise, and a continued focus on value creation and strategic investment.
• Employees: Positive impact through continuity in leadership and a clear focus on achieving corporate goals, potentially leading to job security and growth opportunities.
• Customers (future patients): Positive impact as strong financial management supports the advancement of promising clinical pipeline candidates like CAN-2409, aiming to deliver clinically meaningful solutions.
• Creditors/Investors: Enhanced confidence due to a CFO with a track record of disciplined capital management and successful fundraising, indicating financial stability.

Next Steps

• Advance clinical pipeline.
• Prepare for Biologics License Application (BLA) submission for CAN-2409 in localized prostate cancer.
• Execute on nearand long-term corporate goals.
• Maintain financial stability.
• Strategically invest in the future.
• Drive value for stakeholders.
• Deliver clinically meaningful solutions to cancer patients in need.

Key Dates

Recommendation

Keywords

Candel Therapeutics, CADL, Charles Schoch, Chief Financial Officer, CFO appointment, biopharmaceutical, clinical-stage, SEC filing, 8-K, corporate governance, financial leadership, capital raise, CAN-2409, prostate cancer, immunotherapy, Nasdaq